Iprabronch

Ipratropium bromide, the active ingredient in Iprabronch, is an anticholinergic bronchodilator presented as an inhalation solution for inhalation use. It is employed to relieve bronchoconstriction in patients with chronic obstructive pulmonary disease and asthma, and is used for both maintenance therapy and acute symptom relief.

GNH USA supplies Iprabronch as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable logistics for global distribution and regulatory support to meet local import requirements.

Ipratropium bromide acts on the muscarinic receptors of the airway smooth muscle to provide bronchodilation in obstructive lung diseases.

- COPD: improves airflow and reduces frequency of exacerbations - Asthma: helps control bronchospasm and improves symptom relief - Chronic bronchitis: decreases sputum production and eases breathing

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Cough: mild irritation of the airway - Dry mouth: reduced salivary secretion - Throat irritation: discomfort after inhalation - Headache: transient mild headache - Dizziness: occasional light‑headedness - Nasal dryness: dryness of nasal mucosa

Serious or Rare Side Effects: - Paradoxical bronchospasm: worsening of breathing difficulty - Allergic reactions: rash, itching, or angioedema - Tachycardia: rapid heart rate - Urinary retention: difficulty emptying bladder - Severe hypersensitivity: anaphylaxis (rare)

Before prescribing ipratropium bromide, clinicians should consider several safety and handling factors.

- Assess lung function: confirm diagnosis of COPD or asthma prior to initiation - Avoid in hypersensitivity: do not use in patients with known allergy to ipratropium or formulation components - Monitor glaucoma: use cautiously in patients with narrow‑angle glaucoma - Observe urinary retention: watch for signs in patients with prostatic hypertrophy or bladder outlet obstruction - Adjust for renal impairment: consider dose modification in severe renal dysfunction - Store at room temperature: keep in original container, protect from moisture and light

Ipratropium bromide can interact with other medications, influencing anticholinergic load or bronchodilator response.

Major Interactions (Avoid): - Concurrent anticholinergics: increased risk of anticholinergic side effects such as dry mouth and urinary retention - Combined use with tiotropium: duplication of muscarinic blockade may lead to excessive bronchodilation and systemic effects

Moderate Interactions (Monitor Closely): - Beta‑2 agonists: additive bronchodilation may enhance therapeutic effect, monitor for tachycardia - Theophylline: possible increase in serum levels, observe for toxicity - Antihistamines: may augment anticholinergic burden, watch for cognitive effects - Antidepressants with anticholinergic properties: monitor for additive side effects